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ABSTRACT: Analytical methods based on mass spectrome-
try (MS) have been successfully applied in biomarker
discovery studies, while the role of MS in translating biomarker
candidates to clinical diagnostics is less pronounced.
MALDImmunoassaysmethods that combine immunoaﬃn-
ity enrichment with matrix-assisted laser desorption ionization
time-of-ﬂight (MALDI-TOF) mass spectrometric detection
are attractive analytical approaches for large-scale sample
analysis by virtue of their ease of operation and high-
throughput capabilities. Despite this fact, MALDImmuno-
assays are not widely used in clinical diagnostics, which is
mainly due to the limited availability of internal standards that
can adequately correct for variability in sample preparation and the MALDI process itself. Here we present a novel
MALDImmunoassay for quantiﬁcation of insulin-like growth factor 1 (IGF1) in human plasma. Reliable IGF1 quantiﬁcation in
the range of 10−1000 ng/mL was achieved by employing 15N-IGF1 as internal standard, which proved to be an essential feature
of the IGF1 MALDImmunoassay. The method was validated according to U.S. Food and Drug Administration (FDA) guidelines,
which included demonstrating the eﬀectiveness of IGF1/IGF binding protein (IGF1/IGFBP) complex dissociation using sodium
dodecyl sulfate (SDS). Furthermore, the MALDImmunoassay compared well with the IDS-iSYS IGF1 immunoassay with high
correlation (R2 = 0.99), although substantially lower levels were reported by the MALDImmunoassay. The method was tested on
>1000 samples from a cohort of renal transplant recipients to assess its performance in a clinical setting. On the basis of this
study, we identiﬁed readouts to monitor the quality of the measurements. Our work shows that MALDI-TOF mass spectrometry
is suitable for quantitative biomarker analysis provided that an appropriate internal standard is used and that readouts are
monitored to assess the quality of the measurements.
The number of newly discovered biomarker candidates hasincreased dramatically in recent years following the rise of
modern omics approaches. However, only few of these
biomarkers have made their way into clinical practice.1 This
discrepancy reﬂects the gap between biomarker discovery and
validation and stresses the need for breaking the bottleneck(s)
of the biomarker development pipeline.2−4 To address this
need, many eﬀorts are currently being deployed to translate
biomarker research into clinical practice.1,2,5
In the past decade, mass spectrometry (MS) has found wider
acceptance in biomarker validation studies.4,5 In particular, the
combination of immunoaﬃnity enrichment and matrix-assisted
laser desorption/ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry is gaining momentum. This approach, which we
denote by the generic term “MALDImmunoassay”, holds
considerable promise for biomarker validation studies because
of its ease of use as well as its automation and multiplexing
capabilities.6 In fact, a substantial number of these approaches
have been described in the past years, including various MSIA
(mass spectrometric immunoassay) (i.e., on-target elution of
intact proteins/peptides which are enriched using antibody-
coated microcolumns),7−21 SISCAPA-MALDI (i.e., spotting of
proteotypic peptides which are enriched using antibody-
conjugated magnetic beads),22,23 and iMALDI methods (i.e.,
spotting of antibody-conjugated magnetic beads containing
enriched proteotypic peptides)24−28 as well as other approaches
without distinct denominations.29−34
In light of the potential application of MALDImmunoassays
in clinical diagnostics, it is important to note that MALDI-TOF
MS has already made its entrance into routine clinical practice.
Bruker’s Biotyper and bioMeŕieux’s Vitek are two approved
analytical platforms that have transformed species determi-
nation in medical microbiology.35 Although clinical application
of MALDI-TOF MS has been successful for microbial species
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determination, its application for biomarker quantitation has
not yet reached its full potential, and challenges for
MALDImmunoassays are still numerous and substantial. In
particular, a cornerstone of high-quality quantitative assays is
good internal standardization.34 As MALDImmunoassays
employ antibodies which may be sources of variation, an
internal standard must be able to compensate for variability
during the immunoaﬃnity enrichment step.36 Furthermore,
inasmuch as MALDI-TOF detection is known for its nonlinear
relationship between signal intensity and analyte concentration,
internal standards (preferably stable-isotope-labeled, SIL) must
also compensate for detection variability.37 Indeed, most
MALDImmunoassays employ internal standards, although
some of these standards exhibit substantial structural and
chemical diﬀerences compared to the authentic analyte.34
Therefore, some methods may beneﬁt from improving the
internal standardization which may even advance their
maturation into clinical diagnostics.
An example of a clinically relevant biomarker that has been
targeted by MALDImmunoassays is insulin-like growth factor 1
(IGF1).9,18 IGF1, a 7.65 kDa polypeptide hormone, is the main
mediator of growth hormone (GH)-stimulated cell and tissue
growth. In laboratory medicine, IGF1 is routinely measured to
diagnose GH deﬁciency as well as to test for an excess of GH
leading to abnormal growth in children (e.g., gigantism) or as
the result of a pituitary tumor (e.g., acromegaly).18
Furthermore, IGF1 is an important measure to detect abuse
of GH and IGF1 in sport, and numerous IGF1 measurements
are annually conducted in the ﬁeld of doping analysis.38,39
The most recently published IGF1 MALDImmunoassay is a
high-throughput assay based on the MSIA principle.18 This
method employs speciﬁc antibody-coated microcolumns that
are compatible with selected liquid handling platforms, and is
thereby capable of measuring >1000 samples per day. The
method employs the doping agent LONGR3IGF1 as internal
standard, which is an IGF1 analogue with increased potency
due to a lower binding aﬃnity to circulating IGF binding
proteins (IGFBPs) compared to IGF1.38 This feature, however,
likely aﬀects the appropriateness of LONGR3IGF1 as internal
standard for IGF1, since it implies that this analogue may not
correct adequately for the extraction of IGF1 from IGFBP-
containing matrixes, such as serum and plasma. Furthermore,
the two additional methionine residues in the N-terminal
extension of this protein may lead to formation of diﬀerent
oxidation products compared to IGF1 during the analytical
procedures.38 Thus, chemical diﬀerences between IGF1 and
LONGR3IGF1 may cause variation in the signals for both
compounds.
In this work, we present a MALDImmunoassay for
quantiﬁcation of IGF1 in human plasma which uses a fully
15N-labeled recombinant version of IGF1 as internal standard.
The method was validated according to U.S. Food and Drug
Administration (FDA) guidelines,40 and its performance was
subsequently tested in a clinical setting using >1000 samples
from a cohort of renal transplant recipients. On the basis of this
large-scale study, we identiﬁed indicators of measurement
quality which may aid in making MALDI-TOF MS a reliable
bioanalytical assay platform.
■ EXPERIMENTAL SECTION
Materials. Recombinant human IGF1 (cat. no. CYT-216),
15N-IGF1 (cat. no. CYT-128), and IGFBP3 (cat. no. CYT-300)
were purchased from ProSpec (Ness-Ziona, Israel). Polyclonal
anti-IGF1 antibody (cat. no. PA0362) was obtained from Cell
Sciences (Newburyport, MA, U.S.A.). Pierce Protein A/G
magnetic beads (cat. no. 88802/3) were acquired from Fisher
Scientiﬁc (Landsmeer, The Netherlands), and these were
separated using a Promega MagnaBot 96 separation device.
Acetonitrile (ACN; LC−MS grade) was purchased from
Biosolve (Valkenswaard, The Netherlands), sinapinic acid
(cat. no. M002) was from LaserBio Laboratories (Sophia-
Antipolis, France), and polystyrene U-bottom microtiter plates
(cat. no. 650-101) were obtained from Greiner Bio-One
(Alphen aan den Rijn, The Netherlands). All other chemicals
were purchased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands).
Plasma Samples. For method development and prepara-
tion of QC samples, a bulk quantity of human plasma from
Seralabs (West Sussex, U.K.) was used. This plasma was either
used directly as QC-medium sample, diluted four times with rat
plasma (obtained from Seralabs) to prepare the QC-low
sample, or fortiﬁed with recombinant IGF1 to obtain the QC-
high sample. Spike recovery experiments were carried out using
six diﬀerent sources of human plasma (all from Seralabs). For
method testing, 1038 plasma samples were analyzed from a
cohort of renal transplant recipients (plus screened donors and
healthy controls) that is being studied at the University Medical
Center Groningen (UMCG).41 For this study, ethical approval
has been granted by the UMCG’s review board (METc 2008/
186), and the study adheres to the Declaration of Helsinki.
Blood was collected in plastic K2EDTA tubes (BD, cat. no.
367525) and centrifuged for 10 min at 1300g at room
temperature. After collecting the plasma fraction, samples were
aliquoted into 2 mL polypropylene storage tubes (Sarstedt, cat.
no. 72.609). Samples were stored at −80 °C until further
analysis.
Calibrants and Internal Standard. Lyophilized IGF1 was
reconstituted in 2% ovalbumin (in 100 mM PBS, pH 7.2) to
obtain a 200 μg/mL solution. This solution was diluted to 10
μg/mL with rat plasma or 2% ovalbumin to obtain a stock
solution for calibration or sample fortiﬁcation purposes,
respectively. Using the stock solution in rat plasma, calibration
samples were prepared in rat plasma at 10, 20, 50, 100, 200,
500, and 1000 ng/mL. For the internal standard (IS),
lyophilized 15N-IGF1 was reconstituted in 10 mM ammonium
bicarbonate to obtain a 500 μg/mL solution. After checking the
compound’s (isotopic) purity by MALDI-TOF MS, the stock
was diluted sequentially in 2% ovalbumin to obtain a 400 ng/
mL IS working solution.
Immunoaﬃnity Enrichment. Three microliters of mag-
netic beads was washed thrice with 100 μL of wash buﬀer (0.1%
Tween-20 in 100 mM PBS, pH 7.2) and incubated (1 h; 750
rpm) in 100 μL of wash buﬀer containing 0.5 μg of antibody.
Next, unbound antibody was removed following three washing
steps with 100 μL of wash buﬀer. During incubation of the
beads with the antibody, 20 μL of sample was combined with
10 μL of IS working solution, and the sample was incubated (5
min; 900 rpm) to allow complexing of the IS with the IGFBPs.
Subsequently, 50 μL of dissociation buﬀer (0.3% SDS in wash
buﬀer) was added, and the sample was incubated (30 min; 900
rpm) to enable dissociation of IGF1/IGFBP complexes. After
diluting the dissociated sample with 50 μL of wash buﬀer, this
mixture was added to the antibody-conjugated beads for
immunoaﬃnity enrichment of IGF1 (1 h; 750 rpm).
Subsequently, the beads were washed thrice with 100 μL of
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wash buﬀer and once with 100 μL of Milli-Q water, prior to
elution of IGF1 from the beads (10 min; 900 rpm) with 20 μL
of elution solution (0.45% TFA plus 33% ACN in H2O).
Finally, 5 μL of eluate was mixed 1:1 with a saturated solution
of sinapinic acid in elution solution, and 1 μL of this mixture
was spotted in quadruplicate onto a polished steel MALDI
target plate. The immunopuriﬁcation workﬂow was automated
with an Agilent Bravo liquid handling platform equipped with a
96-channel LT pipetting head.
MALDI-TOF MS. Linear positive MALDI-TOF spectra were
recorded between 4000 and 10 000 Da with a Bruker
ultraﬂeXtreme mass spectrometer operated under Bruker
ﬂexControl software (version 3.4). Acquisition was performed
under the following conditions: 50 ns delayed extraction; signal
deﬂection up to m/z 4000; 2 kHz Smartbeam-II UV laser
(Nd:YAG; λ = 355 nm) operating with the “4_large” parameter
set; 5 GS/s digitizer sampling rate; ion source 1, 2, and lens
voltages of 25.00, 23.30, and 5.75 kV, respectively. For every
sample, 2500 shots were acquired in 100 shot steps following a
“hexagon” measuring raster, although only spectra of suﬃcient
resolution (≥500, after “Centroid” peak detection (peak width
= 5 m/z) using “TopHat” baseline subtraction) were averaged
for each mass spectrum.
Data Processing. MALDI spectra were smoothed
(SavitzkyGolay ﬁlter; width = 5 m/z; cycles = 1), baseline-
subtracted (median; ﬂatness = 0.1; median level = 0.5), and
peaks were detected and integrated (centroid algorithm; peak
width = 5 m/z) using Bruker ﬂexAnalysis software (version
3.4). Peak intensity values for the IGF1 and 15N-IGF1 peaks as
well as for their oxidation peaks were retrieved from obtained
mass lists and processed further using customized Microsoft
Excel (versions 2010 and 2013) spreadsheets.
Method Validation. The method was validated based on
FDA guidelines on bioanalytical method validation.40 The
following criteria were addressed: selectivity (e.g., spike
recovery and IGFBP3 challenge test), accuracy and precision,
calibration curve, and stability (e.g., 24 h benchtop, 3× freeze−
thaw, and 7 days MALDI sample stability). With respect to the
selectivity tests, samples were spiked with IGF1 (25, 100, and
500 ng/mL) or IGFBP3 (2500 ng/mL; protein was
reconstituted and diluted in 2% ovalbumin), and incubated
for 30 min prior to analysis with the MALDImmunoassay. This
incubation step was included to allow complexing of IGF1 with
IGFBP3 and other IGF binding proteins. Furthermore, the
method was compared with the IDS-iSYS IGF1 assay using a
cohort consisting of 20 “normal” samples and 20 samples from
patients with growth hormone deﬁciency or excess.42
■ RESULTS AND DISCUSSION
Characterization of Mass Spectra. Figure 1A shows a
linear positive MALDI-TOF MS spectrum representative of the
clinical samples that were measured. The intense peaks at m/z
7650 and 7743 represent IGF1 and 15N-IGF1, respectively.
Both peaks are accompanied by their sinapinic acid adduct
peaks (+206 mass units), as well as by a peak around m/z 8350,
which was previously observed and denoted as a possible IGF1
variant.18 Figure 1A also features a zoom-in of the spectrum
between 7.6 and 7.8 kDa, clearly displaying the oxidation peaks
of both IGF1 and 15N-IGF1, which likely arise as the result of
oxidation of the methionine residue at position 59. The percent
abundance of these oxidation peaks (relative to the cumulative
intensity of the oxidized and nonoxidized peaks) was
monitored, and on average, oxidation peak abundances for
IGF1 and 15N-IGF1 were around 15% for the clinical samples.
In order to assess analytical accuracy, the constancy of the ratio
between these abundances was monitored and ensured for all
samples (see the Quality Assessment of MALDI Measurements
section).
Figure 1B displays a spectrum that contains an additional
IGF1 signal at m/z 7680, which was observed in one out of
more than 1000 clinical samples. This IGF1 variant has been
observed previously and could originate from a nonsynon-
ymous single-nucleotide polymorphism (SNP) giving rise to an
alanine-to-threonine substitution at position 67 (rs17884626)
or 70 (rs151098426).18,43 In samples from patients carrying
these SNPs, a large discrepancy can be expected between IGF1
levels based on wild-type IGF1 as obtained with the
MALDImmunoassay and those that are obtained with conven-
tional immunoassays or even with available liquid chromatog-
raphy−mass spectrometry (LC−MS) methods targeting
Figure 1. (A) MALDImmunoassay spectrum of IGF1 in plasma from an individual expressing wild-type IGF1 and (B) from an individual expressing
wild-type IGF1 and an IGF1 variant giving rise to a 30 m/z mass increase which likely arises from an alanine-to-threonine substitution at position 67
or 70. Besides peaks originating from IGF1 and 15N-IGF1, MALDI spectra also displayed peaks representing sinapinic acid adducts of IGF1 (†) and
15N-IGF1 (‡) as well as an unknown peak that was previously (ref 18) denoted as a possible IGF1 variant (§). In addition, panel A features a zoom-
in of the spectrum between 7.6 and 7.8 kDa displaying oxidation peaks of IGF1 and 15N-IGF1.
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proteotypic IGF1 peptides that do not cover the regions
relevant for detection of these SNPs. Intensities of the peaks at
m/z 7650 and 7680 may be summed up to give the total
concentration of these IGF1 proteoforms; however, it is
currently unknown whether the biological potencies of these
variants are the same as the potency of wild-type IGF1.
Selection of Internal Standard and Calibration Matrix.
For quantitative MALDI-TOF MS (and quantitative MS
methods in general), calibration is ideally performed with
authentic analyte in authentic matrix and by using an SIL
version of the authentic analyte as internal standard (IS).44,45
Given that IGF1-free human plasma was not available, we
studied the applicability of several surrogate matrixes, including
bovine serum albumin in PBS and plasma from other species.
Corresponding experiments indicated that a high degree of
similarity between the authentic and surrogate matrix was
needed, notably to compensate for technical variation during
the IGF1/IGFBP complex dissociation step and for the
inﬂuence of sodium dodecyl sulfate (SDS) during the
subsequent immunocapture of IGF1. Ultimately, rat plasma
was selected as surrogate matrix since it enables reliable IGF1
quantitation (as demonstrated during method validation; see
below), and because its constituents and rat IGF1 in particular
do not interfere with measuring human IGF1 or the internal
standard (as depicted in Figure S-1). In addition, rat plasma
does not give rise to signals that interfere with known
endogenous IGF1 variants (e.g., des(1−3)IGF1, IGF1 A67T,
and IGF1 A70T) or synthetic IGF1 analogues that may be used
as doping agents (e.g., R3IGF1 and LONGR3IGF1).
As mentioned above, SIL versions of analytes are the
preferred internal standards for MALDImmunoassays. Such
standards allow accurate compensation for variability in both
sample preparation and MS detection; however, SIL analogues
are not readily available for every protein. In cases when such
analogues are not available, alternative internal standards (e.g.,
close structural analogues) may be appropriate, though
justiﬁcation of their applicability must be supported by full
method validation according to internationally recognized
guidelines (e.g., EMA, FDA, and/or CLSI guidelines).46
Diﬀerences in analytical behavior between analytes and
alternative internal standards should ideally be absent, though it
is not inconceivable that diﬀerences become apparent, which
we experienced when using LONGR3IGF1 as internal standard
for IGF1.18 We found that LONGR3IGF1 is not an ideal
internal standard for IGF1, since an equimolar mixture of both
compounds yielded an over 5-fold higher intensity for IGF1
compared to LONGR3IGF1. More importantly, some MALDI-
TOF spectra revealed three oxidation peaks for LONGR3IGF1
compared to only one for IGF1 (see Figure S-2). Most
probably, the two additional methionine residues of the LONG
peptide were oxidized and gave rise to these peaks. On the
contrary, ionization eﬃciency and oxidation behavior of 15N-
IGF1 were highly similar to IGF1 (see Figure 1), and therefore,
we employed 15N-IGF1 as internal standard to accurately
compensate for variability during the entire analytical
procedure.
Assay Characteristics. Results from the method validation
experiments are included in Tables S-1−S-10 (Supporting
Information), while Table 1 displays a concise summary of the
validation data. The calibration curve (1/x weighting) consisted
of seven nonzero standards with values ranging from 10 ng/mL
(LLOQ: CV and bias ±20%) to 1000 ng/mL. Signal intensities
based on peak height and peak area were both evaluated during
method validation, yet peak height was ultimately selected for
calculation of the IGF1 levels as it gave more accurate results,
which has also been reported previously.34,47,48
Evaluation of accuracy and precision as well as all stability
assessments demonstrated biases and coeﬃcients of variation
(CVs) within ±15%. Notably, observed CVs were lowest for
the midrange QC samples, which has also been observed by
others.22,34,49,50 For corresponding IGF1 levels, the analyte and
internal standard were present on the MALDI spot in near
equimolar amounts, which appears to be favorable for the
internal standard’s eﬀectiveness in correcting for variation
arising from the MALDI-TOF process. This eﬀect was further
demonstrated by calculating 4-spot CVs for each sample and by
relating these to the corresponding (4-spot) IGF1/15N-IGF1
ratios (Figure S-3 displays graphical representations of these
relationships for four selected analytical runs carried out for
clinical sample analysis). Observed variation was typically
lowest for IGF1/15N-IGF1 ratios around 1 and increased with
both higher and lower ratios. These observations illustrate the
generally limited span of calibration ranges for MALDI-TOF
MS-based quantitative methods. Furthermore, these results also
Table 1. Summary of Validation Dataa
QC-low QC-medium QC-high
CV (%) bias (%)b CV (%) bias (%)b CV (%) bias (%)b
accuracy and precision (3 runs in 6-fold) run 1 5 1 5 8 13 4
run 2 6 −4 4 −6 15 −10
run 3 10 2 4 −2 15 6
benchtop stability (24 h, in 3-fold) 14 −9 1 9
freeze−thaw stability −20 °C (3 cycles, in 3-fold) 6 −13 4 12
MALDI sample stability (7 days, in 6-fold) day 0 5 1 5 8 13 4
day 7 3 10 4 10 4 12
20 ng/mL calibrant QC-low QC-medium
CV (%) bias (%) CV (%) bias (%)b CV (%) bias (%)b
IGFBP3 challenge test (in 5-fold) 5 −7 4 −6 1 −2
+25 ng/mL +100 ng/mL +500 ng/mL
CV (%) bias (%) CV (%) bias (%) CV (%) bias (%)
spike recovery (6 diﬀerent plasma samples) 9 4 7 11 12 4
aAn extensive summary of the validation results is presented in Tables S-1−S-10 (Supporting Information). bThe average value of measured
concentrations during the precision and accuracy experiments was used as nominal concentration.
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.7b01125
Anal. Chem. 2017, 89, 6188−6195
6191
emphasize the need to match the amount of spiked internal
standard to the median of expected concentrations, or to the
level that is most important for clinical decision making.
It is of particular relevance for quantitative IGF1 assays to
ensure that IGF1 is properly liberated from its binding proteins
(e.g., IGFBP3) and to demonstrate that these binding proteins
do not interfere with the assay. For this assay, disruption of
IGF1/IGFBP complexes was realized by treating samples with
SDS, similar to the approaches of previously published IGF1
methods.9,18,38,51−53 The eﬀectiveness of this step was
demonstrated by means of an IGFBP3 challenge test, in
which calibration and QC samples were spiked with an excess
of IGFBP3, as well as through spike recovery experiments using
six diﬀerent sources of human plasma. After the samples were
spiked with IGFBP3 or IGF1, they were incubated for 30 min
to allow IGF1/IGFBP complex formation. Subsequently,
samples were analyzed with the MALDImmunoassay to assess
accuracy and precision. Results of these experiments showed
that SDS treatment does not introduce a signiﬁcant bias or
imprecision into the assay (±15%), and thereby demonstrate
(to our understanding for the ﬁrst time) the eﬀectiveness of an
SDS-based strategy for IGF1/IGFBP complex dissociation.
The MALDImmunoassay was compared with the IDS-iSYS
IGF1 immunoassay using a set of 40 clinical samples42
(corresponding scatter and Bland−Altman plots are shown in
Figure 2). The negative intercept of the regression line in
Figure 2A and the positive relative diﬀerences in Figure 2B
indicate that there is a bias between the measurements with the
IDS-iSYS IGF1 immunoassay giving higher values than the
MALDImmunoassay. This bias may be explained by the
diﬀerent assay principles of both methods. With the
MALDImmunoassay, IGF1 levels are calculated solely based
on the response of IGF1 with a mass of 7649 Da, while the
IDS-iSYS IGF1 immunoassay may also respond to other IGF1
proteoforms, such as des(1−3)IGF1, proteolytic fragments, and
potential post-translational modiﬁcations of IGF1 that escape
the MALDImmunoassay.
Moreover, Figure 2 indicates that there are two regions with
diﬀerent biases, one for lower IGF1 concentrations (below
±150 ng/mL) and one for higher IGF1 concentrations (above
±150 ng/mL). For the lower concentrations, there is a relative
diﬀerence between the assays of approximately 60% which
decreases to about 20% for the higher concentrations. Lower
values for the MALDImmunoassay may be due to preanalytical
variables leading to a reduced availability of wild-type IGF1
(e.g., proteolytic degradation, methionine oxidation) or may be
caused by incomplete IGF1 extraction from speciﬁc plasma
samples. Higher levels for the IDS-iSYS IGF1 immunoassay
may be the result of cross-reactivity of the antibodies, which
cannot be checked due to the detection principle of this assay.
In order to elucidate the reason(s) for the observed bias, further
research is needed.
As for the above-mentioned preanalytical variables, we must
acknowledge that potential degradation products may be
“missed” by the MALDImmunoassay. Yet, this characteristic
could either be an advantage or a disadvantage of this assay
depending on which samples and clinical questions are being
studied. The MALDImmunoassay has the distinct advantage
over IGF1 immunoassays that the levels obtained are based on
deﬁned chemical information and thereby relate to one IGF1
proteoform with a given potency, whereas methods that
respond to multiple IGF1 proteoforms with diﬀerent potencies
yield IGF1 levels that cannot be directly related to potency. In
particular, des(1−3)IGF1 and LONGR3IGF1 are known to be
more potent than wild-type IGF1, which is presumably caused
by altered binding aﬃnities toward IGFBPs as a result of N-
terminal structural diﬀerences.38,54 The MALDImmunoassay
discriminates wild-type IGF1 from these variants and thereby
allows separate detection of these variants in the same
experiment. When including calibrants and proper internal
standards for these compounds, the resulting assay may even be
used to quantify speciﬁc variants, which could be of interest, for
example, in the ﬁeld of doping analysis. Ultimately, one method
is not necessarily better than the other, and the choice of the
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method for speciﬁc applications should depend on the available
samples as well as the relevant clinical questions.
Quality Assessment of MALDI Measurements. To
study the performance of the MALDImmunoassay more
extensively, the method was applied to over 1000 clinical
samples (analysis and interpretation of the clinical data will be
reported in future publications). Ninety-six samples were
processed per analytical run (i.e., 81 clinical samples, 8
calibrants, 1 blank, and duplicate QC-L, QC-M, and QC-H
samples), and the full set of samples was analyzed within 2
weeks. After a few runs, we observed that more time was
needed per sample to reach the required number of acceptable
spectra (with suﬃcient resolution). Peaks that fulﬁlled the
preset acquisition speciﬁcations could not be found easily, and
total MALDI measurement time increased signiﬁcantly as a
consequence. Ultimately, we found that this prolongation of
analysis time was due to accumulation of matrix deposits in the
MALDI source, and that this prolongation could be reversed by
cleaning the source. Cleaning, however, necessitates venting of
the instrument, so it goes hand in hand with considerable
instrument downtime. Thus, maintaining good analytical
quality comes at the price of reducing the method’s (weekly)
throughput.
To assess whether matrix deposits in the source aﬀect data
quality, we searched for readouts that allowed monitoring of
data quality. In this regard, we observed that in parallel with the
increasing analysis time the relative abundances of oxidation
peaks also increased (Figure 3A, runs 1, 4, and 8). These
abundances decreased again after cleaning of the source (Figure
3A, run 12), thereby conﬁrming that accumulating deposits in
the source led to increased IGF1 oxidation during MALDI-
TOF analysis, which is most likely due to prolonged exposure
of the samples to UV irradiation. Subsequently, we calculated
the ratio between the relative oxidation peaks of IGF1 and 15N-
IGF1, since methionine oxidation is not necessarily problematic
if the internal standard can correct for this phenomenon. Figure
3B shows these ratios for four of the analytical runs carried out
for clinical sample analysis (i.e., runs 1, 4, 8, and 12) and
indicates that corresponding distributions are slightly diﬀerent
for the displayed runs. The impact of these diﬀerences on the
reported IGF1 levels is, however, limited, which becomes
apparent when comparing “regularly calculated” IGF1 levels
with IGF1 levels that are calculated using the sum of peak
intensities from both nonoxidized and oxidized IGF1 (see
Figure S-4). The diﬀerences between the obtained concen-
trations are well within ±15%, with the exception of two
samples for run 8 (see Figure S-5), and indicate that data was
not substantially aﬀected by matrix deposits in the source.
Nonetheless, these ﬁgures highlight the signiﬁcance of an
appropriate cleaning interval for the MALDI source and also
emphasize the need for using 15N-IGF1 as internal standard.
Eventually, we believe that monitoring oxidation peaks would
be of interest for IGF1 (and potentially also for other
methionine-containing proteins) as it enables one to follow
changing conditions in the MALDI source thus allowing to
establish criteria for regular cleaning.
Besides evaluating oxidation peak abundances, we also
monitored the variation between the results obtained for the
diﬀerent MALDI spots belonging to the same sample.
Following the calculation of 4-spot CV values for every sample,
a straightforward measure for monitoring MALDI measure-
ment quality was obtained, which is not dependent on an
analyte’s chemical composition (e.g., whether it contains one or
more methionine residues). Figure 4 shows observed 4-spot
CV values plotted against the corresponding IGF1/15N-IGF1
ratios for the samples of a run that was performed under
optimal analytical conditions (run 1) and for samples that were
obtained with a “dirty” source (run 8). This graph is rather
revealing in several ways. First, the patterns of both data series
show that variation is typically lowest when IGF1 and the IS are
present in equimolar amounts. This ﬁnding is in line with our
previous observation that the precision for the midrange QC
samples was better than that of the QC-low and QC-high
samples (see above). Second, 4-spot variation is clearly larger
when the source contains matrix deposits and thus is in need of
cleaning. We adopted a 4-spot CV cutoﬀ value of 10% to
Figure 3. (A) Bee swarm plots of the relative abundance of the IGF1 oxidation peak and (B) the ratio of the IGF1 and 15N-IGF1 relative abundances
as observed in 4 (of the 13) analytical runs carried out for clinical sample analysis. With respect to the selected runs, the MALDI source was cleaned
after run 8; thus, runs 1, 4, and 8 are shown to illustrate the eﬀect of an increasing level of matrix deposits in the source, and run 12 is shown to
illustrate the eﬀect of cleaning the source. In order to calculate the relative abundances, the peak intensity of the oxidized analyte was divided by the
sum of the peak intensities from the “native” and the oxidized analyte. To calculate the ratio, the relative abundance of the IGF1 oxidation peak was
divided by the relative abundance of the 15N-IGF1 oxidation peak.
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ensure acceptable measurement quality. All samples with 4-spot
CVs exceeding this value were reanalyzed with a clean source
which resulted in CVs well below 10%. Admittedly, monitoring
4-spot variation necessitates using multiple spots per sample
which aﬀects the method’s throughput. Nevertheless, we
recommend to monitor this quality indicator to ensure accurate
data acquisition and to follow accumulation of matrix deposits
in the source (additional data that support this recommenda-
tion are shown in Figure S-7 and Tables S-11 and S-12).
■ CONCLUSIONS
We describe a MALDImmunoassay for quantiﬁcation of IGF1
in human plasma which complies with current international
guidelines on quantitative bioanalysis. The assay shows good
correlation with the IDS-iSYS IGF1 immunoassay. However, a
positive bias was observed for the IDS-iSYS immunoassay as
compared to the MALDImmunoassay, and the exact reasons
for this bias are still unknown.
MALDImmunoassays combine immunoaﬃnity enrichment
with MALDI-TOF MS detection, and both these methodo-
logical features are known sources of analytical variability.
Consequently, the most critical feature of a reliable quantitative
assay is the application of an appropriate internal standard
which is capable of correcting for these sources of analytical
variability. A SIL version of the full-length analyte is preferred
for MALDImmunoassays, and therefore, 15N-IGF1 was used as
internal standard in our IGF1 MALDImmunoassay. Another
critical step for an IGF1 assay is proper liberation of IGF1 from
its binding proteins which could interfere with the detection of
IGF1. We demonstrate in an IGFBP3 challenge experiment as
well as in spike recovery experiments that the SDS-based
dissociation step is eﬀectively leading to dissociation of the
IGF1/IGFBP complexes.
Application of the MALDImmunoassay to a clinical study
comprising more than 1000 clinical samples indicated that
contamination of the MALDI source led to various degrees of
oxidation of Met59. This variation in IGF1 oxidation was
corrected for by the 15N-IGF1 internal standard emphasizing
the need for a SIL internal standard. Furthermore, variation in
IGF1 oxidation as well as the interspot variation were useful
indicators of MALDI-TOF performance. Therefore, we
recommend to monitor these quality indicators in order to
ensure consistent performance of the assay.
In conclusion, our work reports a validated MALDImmuno-
assay for quantiﬁcation of IGF1 in human plasma and addresses
some of the challenges of MALDImmunoassays that must be
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